Skip to main content
    R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $188.44
    -5.51 (-2.84%)

    Market Cap: $41.48B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    19%(5/27)
    Avg Surprise
    -68.02%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.39
    Range$-3.26 - $-2.07
    21 analysts
    EPS Revisions
    1
    0
    7d
    9
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.99-20.1%
    60d ago$-2.45+2.6%
    30d ago$-2.44+2.1%
    7d ago$-2.40+0.4%
    Current$-2.39
    Revenue Consensus
    $23M
    Range$0 - $56M
    20 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-3.34
    Range$-6.02 - $-1.93
    23 analysts
    Revenue Consensus
    $147M
    Range$-41148720 - $314M
    23 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.34---
    Sep 26EST
    		-$-2.39---
    Jun 26
    Reported Aug 5
    		$-2.34$-1.93-21.24%Miss-78.6%
    Mar 26
    Reported May 6
    		$-2.29$-1.84-24.46%Miss-102.7%
    Dec 25
    Reported Feb 25
    		$-1.86$-1.58-17.72%Miss-66.1%
    Sep 25
    Reported Nov 5
    		$-1.61$-1.39-15.83%Miss-71.3%
    Jun 25
    Reported Aug 6
    		$-1.31$-1.12-16.96%Miss-61.7%
    Mar 25
    Reported May 7
    		$-1.13$-1.06-6.60%Miss-61.4%
    Dec 24
    Reported Feb 26
    		$-1.12$-0.96-16.12%Miss+1.8%
    Sep 24
    Reported Nov 6
    		$-0.94$-0.88-6.82%Miss+5.1%
    Jun 24
    Reported Aug 7
    		$-0.81$-0.76-6.58%Miss+12.0%
    Mar 24
    Reported May 8
    		$-0.70$-0.72+2.78%Beat+2.8%
    Dec 23
    Reported Feb 26
    		$-1.14$-0.88-29.55%Miss-81.0%
    Sep 23
    Reported Nov 6
    		$-0.99$-1.00+1.00%Beat-13.8%
    Jun 23
    Reported Aug 8
    		$-0.92$-0.82-12.20%Miss-12.2%
    Mar 23
    Reported May 8
    		$-0.72$-0.80+10.00%Beat+7.7%
    Dec 22
    Reported Feb 27
    		$-0.63$-0.82+23.17%Beat+11.3%
    Sep 22
    Reported Nov 7
    		$-0.87$-0.85-2.35%Miss-20.8%
    Jun 22
    Reported Aug 9
    		$-0.82$-0.84+2.38%Beat-36.7%
    Mar 22
    Reported May 9
    		$-0.78$-0.77-1.30%Miss-47.2%
    Dec 21
    Reported Feb 28
    		$-0.71$-0.64-10.94%Miss-36.5%
    Sep 21
    Reported Nov 10
    		$-0.72$-0.62-16.13%Miss-71.4%
    Jun 21
    Reported Aug 11
    		$-0.60$-0.56-7.14%Miss-30.4%
    Mar 21
    Reported May 10
    		$-0.53$-0.52-1.92%Miss+28.4%
    Dec 20
    Reported Mar 2
    		$-0.52$-0.38-36.84%Miss+92.0%
    Sep 20
    Reported Nov 12
    		$-0.42$-0.40-5.00%Miss-13.5%
    Jun 20
    Reported Aug 10
    		$-0.46$-0.37-24.32%Miss-
    Mar 20
    Reported May 14
    		$-0.74$-0.36-105.56%Miss-
    Dec 19
    Reported Feb 13
    		$-6.52$-0.41-1490.24%Miss-
    Sep 19
    Reported Nov 27
    		$-0.37$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-23.26EV/EBITDAN/A
    Price/FCF-32.25xFCF Yield-3.10%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-79.10%ROIC-46.15%
    Financial Health
    Debt/Equity0.19xInterest Coverage-30.45x
    Current Ratio11.38xQuick Ratio11.38x
    Trading Statistics
    Beta1.40Avg Volume2.31M
    52-Week High$224.3152-Week Low$52.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$198.65
    SMA 20$197.88
    SMA 50$203.68
    SMA 200$150.02
    EMA 10$195.76
    EMA 20$198.42
    EMA 50$197.50
    EMA 200$155.58

    MACD

    Line: -2.61Signal: -1.19Hist: -1.41

    ADX

    ADX: 21.1+DI: 11.5-DI: 23.8

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down88.0
    PSAR$209.69

    Bollinger Bands

    Upper Band$211.17
    Lower Band$184.60
    %B Position1342%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    38.8

    Momentum Oscillators

    Stoch %K33.0
    Stoch %D34.0
    Williams %R-74.4
    ROC (10d)-7.8%
    Momentum-16.04
    CCI (20d)-99.0
    MFI (14d)49.5

    Volatility Measures

    ATR (14d)$8.66(4.6%)
    StdDev (20d)6.64
    Hist Vol41.6%(High)

    Volume Flow

    VWAP$189.73
    OBV124.2M
    AD Line66.9M
    CMF (20d)-0.092

    Volume Metrics

    Avg Vol (20d)2.4M
    Vol Ratio1.2x
    VWMA (20d)$196.36

    Pivot Points

    R3$206.72
    R2$200.49
    R1$197.22
    Pivot Point$190.99
    S1$187.72
    S2$181.49
    S3$178.22

    Advanced Oscillators

    TSI-11.12
    Ultimate Osc51.8
    KST-33.04

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$261.59M$0$0$0$742,000$0
    Cost of Revenue$0$0$4.70M$0$0$0$188.10M$0$0$0$136.58M$0
    Gross Profit$0$0$-4,702,000$0$0$0$-188,096,000$0$0$0$742,000$0
    Operating Expenses$505.13M$445.22M$361.63M$315.27M$264.71M$240.76M$216.31M$175.71M$156.64M$140.86M$180.72M$123.25M
    R&D$394.92M$343.97M$294.94M$262.51M$224.13M$205.75M$187.52M$151.75M$134.93M$118.02M$148.48M$107.73M
    SG&A$110.21M$101.25M$66.68M$52.76M$40.58M$35.01M$28.79M$23.96M$21.71M$22.84M$32.24M$15.51M
    Operating Income$-505,132,000$-445,222,000$-361,626,000$-315,269,000$-264,714,000$-240,760,000$-216,310,000$-175,712,000$-156,643,000$-140,859,000$-179,983,000$-123,248,000
    Interest Income$35.58M$19.51M$21.29M$22.08M$22.40M$24.91M$21.23M$20.41M$21.49M$23.76M$18.98M$10.95M
    Interest Expense$23.78M$12.20M$3.27M$11.43M$867,000$0$0$0$-16,000$0$0$0
    Income Before Tax$-644,371,000$-453,816,000$-364,892,000$-305,206,000$-247,787,000$-213,416,000$-195,322,000$-156,288,000$-133,233,000$-116,003,000$-161,194,000$-112,301,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$343,000$-3,867,000
    Net Income$-644,371,000$-453,816,000$-364,892,000$-305,206,000$-247,787,000$-213,416,000$-194,569,000$-156,288,000$-133,233,000$-116,003,000$-161,537,000$-108,434,000
    EBITDA$-656,002,000$-459,581,000$-374,132,000$-317,240,000$-273,265,000$-244,432,000$-227,562,000$-182,146,000$-162,841,000$-152,244,000$-185,946,000$-126,247,000
    EBIT$-656,169,000$-460,893,000$-374,280,000$-315,861,000$-269,324,000$-238,331,000$-222,123,000$-175,430,000$-154,736,000$-139,763,000$-180,171,000$-123,248,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RVMD

    News

    RevMed’s pancreatic cancer drug nears European approval

    Revolution Medicines' pancreatic cancer drug is reportedly close to European approval. This news comes alongside developments including Merck and Moderna's plans for cancer vaccine expansion and China's growing influence...

    STAT•10/16/26•Bullish

    Form DEF 14A Revolution Medicines Inc For: 14 October By Investing.com

    This article announces the filing of Form DEF 14A by Revolution Medicines Inc, with the filing date noted as October 14. The information is presented by Investing.com. The article also provides the stock symbol RVMD...

    Investing.com Canada•10/15/26•Neutral

    A pancreatic cancer drug cut the risk of death by 60% versus chemotherapy in a trial.

    Revolution Medicines' RASONQUE (daraxonrasib) has received a positive opinion from the European Medicines Agency's CHMP...

    Stock Titan•10/15/26•Bullish

    Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

    Revolution Medicines announced that its drug RASONQUE (daraxonrasib) has received a positive opinion from the European Medicines Agency's CHMP for marketing authorization in the European Union for treating metastatic...

    Yahoo Finance•10/15/26•Bullish

    Revolution Medicines Daraxonrasib: The Best Inventions of 2026

    Revolution Medicines' drug, Daraxonrasib, has been recognized as one of the best inventions of 2026 for its groundbreaking impact on pancreatic cancer treatment. The targeted drug nearly doubled overall survival...

    Time Magazine•10/15/26•Bullish

    RVMD Valuation and Fair Value

    P/E
    -23.3x
    P/FCF
    -32.3x
    P/B
    15.2x
    See GNG's fair value

    RVMD Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -46.1%
    ROE
    -79.1%
    FCF yield
    -3.1%

    RVMD Competitors

    CompanyTicker
    Haleon plcHLN
    Illumina IncILMN
    Waters CorporationWAT
    IDEXX Laboratories IncIDXX
    IQVIA Holdings IncIQV
    BeiGene, Ltd.ONC
    Teva Pharma Industries Ltd ADRTEVA
    Centene CorpCNC

    Sector: Healthcare

    RVMD Analyst Ratings

    Consensus
    Buy
    Analysts
    23
    Strong Buy
    5
    Buy
    17
    Hold
    1
    Sell
    0
    Strong Sell
    0

    RVMD Bull Case vs Bear Case

    Bull case

    • 95.7% of RVMD's analyst ratings are Buy or Strong Buy.

    Bear case

    • RVMD beat EPS estimates in 0.0% of its last 8 reported quarters.
    • RVMD's quarterly revenue changed -95.2% year over year.

    RVMD Earnings: Beat Rate and Next Report

    Beat rate
    0 of 8 quarters (0.0%)
    Average surprise
    -15.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.39
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    9 up, 3 down

    Frequently Asked Questions About RVMD

    Does RVMD pay dividends?

    Revolution Medicines Inc (RVMD) does not currently pay a regular dividend.

    What is RVMD's market cap?

    Revolution Medicines Inc (RVMD) has a market capitalization of $41.48B with a current stock price of $188.44.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In